{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-052420","form_type":"8-K","ticker":"CYTK","cik":"0001061983","company_name":"CYTOKINETICS INC","filed_at":"2023-10-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.082525+00:00","generated_at":"2026-06-10T03:12:31.920434+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Cytokinetics presents SEQUOIA-HCM baseline data: 282 patients enrolled, results due by end 2023","bullets":["SEQUOIA-HCM enrolled 282 patients with symptomatic obstructive HCM; one third from US, half from Europe/Israel, remainder from China.","Mean age 59.1 years, 40.4% female, 78.7% white; baseline NYHA class II 75.9%, III 23.8%, IV 0.4%.","Background therapy: beta-blockers 61%, calcium channel blockers 26.6%, disopyramide 12.8%.","Key blinded baseline data include LVEF, LVOT gradients, and NT-proBNP; top-line results still expected by end of 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-052420","json":"https://secwatch.observer/filing/0000950170-23-052420.json","markdown":"https://secwatch.observer/filing/0000950170-23-052420.md","text":"https://secwatch.observer/filing/0000950170-23-052420.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1061983/000095017023052420/0000950170-23-052420-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1061983/000095017023052420/cytk-20231006.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T03:12:31.920434+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}